Our story
The natural evolution of insulin delivery
For decades, insulin pen technology has transformed diabetes care. Yet, more than 20 million people worldwide still inject insulin with syringes.
When GO-Pen's co-founders looked at this gap, they saw an engineering opportunity: combine proven pen technology with insulin from vials.
That is how GO-PEN® was born. To us, this isn't about reinventing insulin delivery. It is about bringing the benefits of pen-based delivery to a large, underserved group of insulin users.
Why this hasn't been solved before
The obstacle hasn't been technology. It has been focus. Much of diabetes innovation has focused on increasingly advanced solutions and premium segments. Meanwhile, a large population continue to administer insulin from vials using syringes.
GO-PEN addresses this gap with a reusable insulin pen for vials, built for broader access and commercial scale.
Driven by purpose
GO-Pen is founded on a purpose of creating equal access to quality diabetes care.
Our vision is a world where people using insulin from vials have access to insulin pens.
Our mission is to make GO-PEN widely available by combining intuitive design, accurate dosing and reliable performance in a reusable insulin pen built for broader access and commercial scale.
GO-PEN has moved from an idea to a regulated medical device. With FDA 510(k) clearance and CE marking achieved, and usability testing completed with insulin users, the company is now moving towards commercialisation and scale.
Responsibility
We aim to balance environmental and social impact by creating equal access to quality diabetes care while minimizing environmental impact through evidence-based design and continuous optimization.
This is reflected in the decisions we make about design, production and distribution of our product. Our approach to sustainability stands on the three solid ESG pillars:
Environmental impact
Social impact
Responsible governance
Environmental impact
73% lower carbon footprint
An ISO 14040/44-compliant Life Cycle Assessment (LCA), conducted in collaboration with DTU, compared GO-PEN with 1.0 mL single-use syringes across 1,460 insulin injections, corresponding to one year of treatment with four daily injections in Denmark. Under these assessment conditions, GO-PEN showed a 73% lower carbon footprint.
GO-PEN is designed as a reusable insulin delivery device with an expected lifetime of up to three years, reducing reliance on disposable injection components.
Important context: The results are based on Danish treatment practices and assume single use of syringes in line with Danish healthcare standards. Environmental performance may vary depending on local practices and usage patterns.
Social impact
GO-Pen aims to improve access to insulin pen-based delivery for people who use insulin from vials. By combining vial insulin with a reusable pen platform, GO-PEN is designed to offer an alternative to syringe-based administration and address an unmet need in insulin delivery.
Responsible governance
Our team's combined experience in diabetes care, regulatory excellence, and sustainable business practices guides our decision-making. We consider long-term impact on people, healthcare systems, and environmental outcomes in everything we do.
GO-PEN aligns with the UN Sustainable Development Goals with a particular focus on:
SDG 3: Good Health and Well-being
SDG 8: Decent Work and Economic Growth
SDG 9: Industry, Innovation and Infrastructure
SDG 10: Reduced Inequalities
SDG 12: Responsible Consumption and Production